Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Oral PN-943 in Subjects With Moderate to Severe Active Ulcerative Colitis

NCT04504383 is registered in ClinicalTrials.gov with Protagonist Therapeutics, Inc. as lead sponsor.

NCT NCT04504383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04504383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Oral PN-943 in Subjects With Moderate to Severe Active Ulcerative Colitis
Lead sponsor
Protagonist Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 5, 2020
Completion date
February 16, 2023
Enrollment
169 (actual)
Sites
122

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis chronic moderate, ulcerative colitis chronic severe